Anticancer immunity modulation is the current standpoint of research and has revolutionized
the standard of care of platinum refractory recurrent/metastatic head and neck carcinoma of …

The immune checkpoint inhibitors, a class of drugs able to block immune suppressive
pathways in order to prime an anticancer immunity, revolutionized standard of care in …

Head and neck squamous cell carcinoma (HNSCC) is a frequent tumour arising from
multiple anatomical subsites in the head and neck region. The treatment for early-stage …

As with many types of cancer, immunotherapy is changing the management of squamous
cell carcinoma of the head and neck (HNSCC). In a locally advanced or metastatic setting …

Head and neck squamous cell carcinomas (HNSCCs) are the seventh most common
malignancy worldwide. HNSCCs are highly heterogeneous diseases with varied genetic …

The morbidity and mortality of recurrent/metastatic (r/m) head and neck squamous cell
carcinoma (HNSCC) are still high, despite advances in treatment. HNSCC is known to …

Squamous cell cancer of the head and neck (HNSCC) is the sixth most common cancer and
is associated with significant morbidity and mortality. The tumor microenvironment for …

Despite significant progress and improving outcomes in the management of head and neck
squamous cell carcinoma (HNSCC), there are few effective treatment options for patients …

Head and neck squamous cell cancer (HNSCC) is a malignancy with a rapidly changing
demographic profile, given the recent epidemic of human papilloma virus related cancers …

Introduction: Head and neck squamous cell carcinomas (HNSCC) previously had limited
treatment options once patients had progressed on systemic chemotherapy. With recent …